Lordlans.com - The Original Trending
READ MORE  Government pursuing reforms to make India one of world's top economies: Nirmala Sitharaman - Times of India

Corona Vaccine: Refusal on January 1, Two Ready! How did the expert panel decide on covaxine at the last minute?

0
Covid-19 Vaccine: Drug Controller General of India (DCGI) in India Covaxine (Covaxine) and Covishield (Covishield) emergency use have been approved, after which both companies are now face to face regarding the quality of their vaccines. Bharat Biotech claimed that its cocaine was effective on the corona virus, while the Serum Institute claimed that their vaccine was better than covicillin. The opposition is trying to surround the government after Covaxine was approved to use emergency without all the data. The opposition has made serious allegations against the government and said that the corona virus vaccine has been approved in haste.

In fact, last week, within 24 hours, an expert committee of the Drug Controller General of India changed its decision regarding cocaine. The Expert Committee approved the use of this biotech vaccine of Bharat Biotech by emergency without evidence of efficacy on humans. This big decision was taken in this meeting of the expert committee held on 1 and 2 January.

Bharat Biotech’s covaxine is also completely safe, but not approved for children and pregnant women – AIIMS Director

‘Indian Express’ Has published a detail report regarding the subject expert committee (SEC) meeting. According to the report, the SEC passed the prohibited use of covaxin on 2 January. The very next day i.e. on January 3, Dr. VK Somani, CDSCO of the Drug Controller General of India, approved the use of emergency on the candidate of covaxine.

Bharat Biotech Chairman and MD Dr. Krishna Alla on Monday amidst the ongoing politics on covaxine. Alla said that the politics is being done on the vaccine. He said that some people are gossiping about our vaccine. It should not happen. We are not just an Indian company but a global company.

READ MORE  From Corona vaccine to Ram temple, read here 10 big news of the country and the world

Dr Krishna Alla criticized the critics, asking – ‘Why were such questions not raised on the data of the global trial of AZD1222, a version of the Covishield vaccine produced by Pune-based Serum Institute of India.’

In the SEC meeting on 1 January, it was told by Bharat Biotech that its covicin is capable of targeting the mutation of strains of corona virus. However, the company could not present enough data to substantiate its claim in the meeting. Therefore, the panel could not agree to approve the emergency use of this vaccine. However, on January 2, the SEC changed its decision and covaxine was approved to use emergency. The SEC recommended the emergency use of covaxine, citing efficacy data from a study on non-human heads.

The minutes of the SEC meeting in the public domain stated, ‘The data generated so far reflect a strong immune response (both antibodies as well as T cells) and in-vitro viral neutralization. A clinical trial running on 25,800 Indians is a big trial. It has already nominated 22,000 candidates with some conditions, which are still safe.

It was further stated in the meeting, ‘However, efficacy data is yet to come.’ In the meeting, the SEC panel said, ‘After detailed deliberations, the panel suggests Bharat Biotech to further accelerate the data of its vaccine. Also, in the already ongoing 3-stage hyun trial, more candidates are being asked to be included. The panel also recommended that the company have to file an interim efficacy analysis report on its application for approval of restricted emergency use.

READ MORE  Good news: Health Minister gives hints - Corona vaccine may be approved soon in India

However, in a re-convened meeting a day later, the SEC panel approved the emergency use of covacine made by Hyderabad-based company Bharat Biotech. The panel said that in view of the increasing incidence of newly muted corona virus infection, the Bharat Biotech vaccine could be used on a clinical trial mode of emergency.

Coronavirus Vaccine: Delay in taking second dose of Corona Vaccine will have no effect!

The SEC said, ‘After the above deliberations, the committee has approved the emergency use of covicin as a comprehensive precaution and in public interest. Covaxin will be used in clinical trial mode. So that given the coronation mutations, we have more options for vaccination. Apart from this, Bharat Biotech will also continue the clinical trial of the third phase and will present it before the panel as soon as the final data is collected. ‘

However, Bharat Biotech head Dr Alla made it clear in his briefing on Monday that he had not yet submitted the interim efficacy data report to the panel. Alla said, ‘We have just given the data for the highest antibody response. In which long term immunogenicity and neutralization protection have been described.

Leave A Reply

Your email address will not be published.